Condition: Natural Killer/T-cell Lymphoma · Relapsed or Refractory Lymphoma Including ENKL · Sponsor: Fudan University
This open-label, multicenter Ib/II phase clinical trial investigates the safety, tolerability, and preliminary efficacy of tislezumab (anti-PD-1 monoclonal antibody), golidocitinib (JAK1/STAT3 signaling pathway inhibitor), and selinexor (selective inhibitor of nuclear export, XPO1 antagonist) in patients with relapsed/refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) progressing after ≥1 line of L-asparaginase-containing chemotherapy or chemoradiotherapy.
This description comes directly from the study's public registry record.
Rong Tao, MD & PhD · 008621-64175590 · hkutao@hotmail.com
Chuanxu Liu, MD · 008621-64175590 · liuchaunxu@shca.or.cn
Always discuss trial participation with your own doctor first.
| Dept of lymphoma and medical oncology, Shanghai Cancer Center | Shanghai, Shangai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06966154